



Packet No.: 069738-0011

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Kaiser, Jon D.
Appl. No. : 10/750,545
Filed : December 31, 2003
Title : NUTRIENT COMPOSITIONS AND
METHODS FOR ENHANCED
EFFECTIVENESS OF THE IMMUNE
SYSTEM


Grp./A.U. : 1616
Examiner: : Ernst V. ARNOLD

Customer No.: 41552
Confirmation No.: 5578

CERTIFICATE OF MAILING BY EXPRESS MAIL(37
CFR § 1.10)

"Express Mail" Mailing Label Number EV 643140837 US

I hereby certify that this paper or fee is being deposited with
the United States Postal Service "Express Mail Post Office to
Addressee" service under 37 CFR § 1.10 on the date indicated
above and is addressed to Commissioner for Patents, P.O. Box
1450, Alexandria, VA 22313-1450 on Jan 12, 2006.


Sarah Nunez

INFORMATION DISCLOSURE STATEMENT

Mail Stop IDS
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In accordance with the provisions of 37 C.F.R. 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached form PTO-1449. It is respectfully requested that the documents be expressly considered during the prosecution of this application, and that the documents be made of record therein and appear among the "References Cited" on any patent to issue therefrom.


This Information Disclosure Statement is being filed within three months of the U.S. filing date OR before the mailing date of a first Office Action on the merits. No certification or fee is required.

10/750,545

Please charge any shortage in fees due in connection with the filing of this paper, including extension of time fees, to Deposit Account 502624 and please credit any excess fees to such deposit account.

Respectfully submitted,

McDERMOTT WILL & EMERY LLP




David A. Gay
Registration No. 39,200

4370 La Jolla Village Drive, Suite 700
San Diego, CA 92122
Phone: 858.535.9001 DAG:HGF:llf
Facsimile: 858.597.1585
Date: January 12, 2006

**Please recognize our Customer No. 41552
as our correspondence address.**

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (PTO-1449)	ATTY. DOCKET NO. 069738-0011	SERIAL NO. 10/750,545
	APPLICANT Kaiser, Jon D.	
	FILING DATE December 31, 2003	GROUP 1616



U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS	CITE NO.	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	US 5,916,912	06/29/1999	Ames, et al.	
	2	US 6,063,820	05/15/2000	Cavazza	
	3	US 6,191,162	02/20/2001	Byrd, et al.	
	4	US 6,365,622	04/02/2002	Cavazza	
	5	US 6,479,069	11/12/2002	Hamilton	
	6	US 6,579,544	06/17/2003	Rosenberg, et al.	
	7	US 2003/0206895	11/06/2003	Cavazza	

FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS	CITE NO.	Foreign Patent Document Country Codes-Number 4-Kind Codes (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Figures Appear	Translation	
	8	WO 94/02036	02/03/1994	Metagenics, Inc.		Yes	No
	9	PCT WO 00/11968	03/09/2000	Cavazza			

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER'S INITIALS	CITE NO.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	10	ABBAS et al., "Evaluation of the efficacy of thiamine and pyridoxine in the treatment of symptomatic diabetic peripheral neuropathy," <u>East Afr. Med. J.</u> 74(12):803-808 (1997).
	11	ALLARD et al., "Effects of vitamin E and C supplementation on oxidative stress and viral load in HIV-infected subjects," <u>AIDS</u> 12(13):1653-1659 (1998)
	12	AUKRUST et al., "Glutathione redox disturbances in human immunodeficiency virus infection: immunologic and therapeutic consequences," <u>Nutrition</u> 15(2):165-167 (1999).
	13	BAUR et al., "Alpha-lipoic acid is an effective inhibitor of human immuno-deficiency virus (HIV-1) replication," <u>Klin. Wochenschr.</u> 69(15):722-724 (1991).
	14	BERNSTEIN et al., "Brief communication: effect of pharmacologic doses of vitamin B6 on carpal tunnel syndrome, electroencephalographic results, and pain," <u>J. Am. Coll. Nutr.</u> 12(1):73-76 (1993).
	15	BUHL et al., "Systemic glutathione deficiency in symptom-free HIV-seropositive individuals," <u>Lancet</u> 334(8675):1294-8 (1989).
	16	BUTTKE et al., "Oxidative stress as a mediator of apoptosis," <u>Immunol. Today</u> 15(1):7-10 (1994).
	17	CAMPOS et al., "Plasma carnitine insufficiency and effectiveness of L-carnitine therapy in patients with mitochondrial myopathy," <u>Muscle Nerve</u> 16(2):150-153 (1993).
	18	CHEN et al., "Delayed cytotoxicity and selective loss of mitochondrial DNA in cells treated with the anti-human immunodeficiency virus compound 2',3'-dideoxycytidine," <u>J. Biol. Chem.</u> 264(20):11934-11937 (1989).

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (PTO-1449)	ATTY. DOCKET NO. 069738-0011	SERIAL NO. 10/750,545
	APPLICANT Kaiser, Jon D.	
	FILING DATE December 31, 2003	GROUP 1616

19	CHEN et al., "Effect of anti-human immunodeficiency virus nucleoside analogs on mitochondrial DNA and its implication for delayed toxicity," <u>Mol. Pharmacol.</u> 39(5):625-628 (1991).	
20	CHOI et al., "Molecular mechanism of decreased glutathione content in human immunodeficiency virus type 1 Tat-transgenic mice," <u>J. Biol. Chem.</u> 275(5):3693-3698 (2000).	
21	DALAKAS et al., "Zidovudine-induced mitochondrial myopathy is associated with muscle carnitine deficiency and lipid storage," <u>Ann. Neurol.</u> 35(4):482-487 (1994).	
22	DE QUAY et al., "Glutathione depletion in HIV-infected patients: role of cysteine deficiency and effect of oral N-acetylcysteine," <u>AIDS</u> 6(8):815-819 (1992).	
23	Douglas Laboratories, Inc., "Energizer Formula – Nutritional Support for Mitochondrial Energy Production" (1999).	
24	FAMULARO et al., "Acetyl-carnitine deficiency in AIDS patients with neurotoxicity on treatment with antiretroviral nucleoside analogues," <u>AIDS</u> 11(2):185-190 (1997).	
25	FAMULARO et al., "Treatment with acetyl-L-carnitine has the potential to improve the clinical course of painful peripheral neuropathies in HIV-positives patients," <u>J. Peripher. Nerv. Syst.</u> 3(3):227-229 (1998).	
26	FUCHS et al., "Studies on lipoate effects on blood redox state in human immunodeficiency virus infected patients," <u>Arzneimittelforschung</u> 43(12):1359-1362 (1993).	
27	HERZENBERG et al., "Glutathione deficiency is associated with impaired survival in HIV disease," <u>Proc. Natl. Acad. Sci. USA</u> 94(5):1967-1972 (1997).	
28	Kaiser, M.D., Jon D., Healing HIV How to Rebuild Your System, Health First Press, Mill Valley, California (1999).	
29	KALEBIC et al., "Suppression of human immunodeficiency virus expression in chronically infected monocytic cells by glutathione, glutathione ester, and N-acetylcysteine," <u>Proc. Natl. Acad. Sci. USA</u> 88(3):986-990 (1991).	
30	KHOURI et al., "Lactic acidosis secondary to nucleoside analog antiretroviral therapy," <u>Infect. Med.</u> 17(8):54-554 (2000).	
31	Kuby, Immunology, 3rd Edition, W.H. Freeman & Co., New York (1997).	
32	PACKER et al., "Vitamin E and alpha-lipoate: role in antioxidant recycling and activation of the NF-kappa B transcription factor," <u>Mol. Aspects Med.</u> 14(3):229-239 (1993).	
33	PARKER et al., "Mitochondrial toxicity of antiviral nucleoside analogs," <u>J. NIH Res.</u> 6:57-61 (1994).	
34	PATRICK, ND, Lyn, "Nutrients and HIV: part three - N-acetylcysteine, alpha-lipoic acid, L-glutamine, and L-carnitine," <u>Altern. Med. Rev.</u> 5(4):290-305 (2000).	
35	Paul, W.E., Fundamental Immunology, 3rd Edition, Raven Press, New York (1989).	
36	SATO et al., "Thiol-mediated redox regulation of apoptosis. Possible roles of cellular thiols other than glutathione in T cell apoptosis," <u>J. Immunol.</u> 154(7):3194-3203 (1995).	
37	SCARPINI et al., "Effect of acetyl-L-carnitine in the treatment of painful peripheral neuropathies in HIV+ patients," <u>J. Peripher. Nerv. Syst.</u> 2(3):250-252 (1997).	
38	SHOR-POSNER et al., "Neuroprotection in HIV-positive drug users: implications for antioxidant therapy," <u>J. Acquir. Immune Defic. Syndr.</u> 31 Suppl 2:S84-S88 (2002).	

EXAMINER	DATE CONSIDERED
----------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (PTO-1449)	ATTY. DOCKET NO. 069738-0011	SERIAL NO. 10/750,545
	APPLICANT Kaiser, Jon D.	
	FILING DATE December 31, 2003	GROUP 1616

	39	SIMPSON et al., "Neurologic manifestations of HIV infection," <u>Ann. Intern. Med.</u> 121(10):769-785 (1994). Review. Erratum in: <u>Ann. Intern. Med.</u> 122(4):317 (1995).	
	40	Thorne Research, Inc., "Do You Care About What you Put In Your Body?," http://www.thorne.com/index/mod/rs/a/rs	
	41	UF News, "UF Researcher Finds Vitamins and Exercise May Slow the Harmful Effects of Aging," http://www.napa.ufl.edu/2003news/vitamine.htm (2003).	
	42	WITSCHI et al., "The systemic availability of oral glutathione," <u>Eur. J. Clin. Pharmacol.</u> 43(6):667-669 (1992).	
	43	ZIEGLER et al., "Alpha-lipoic acid in the treatment of diabetic peripheral and cardiac autonomic neuropathy," <u>Diabetes</u> 46 Suppl 2:S62-S66 (1997).	
	44	ZIEGLER et al., "Alpha-lipoic acid in the treatment of diabetic polyneuropathy in Germany: current evidence from clinical trials," <u>Exp. Clin. Endocrinol. Diabetes</u> 107(7):421-430 (1999).	

EXAMINER	DATE CONSIDERED
----------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.